HOOKIPA Pharma Inc. has transferred its oncology-focused therapeutic programs to NeoTrail Therapeutics, Inc., marking a strategic shift in the company's development priorities. The divestiture encompasses two core immunotherapy candidates: Eseba-vec (HB-200) and HB-700, both developed on HOOKIPA's p